Literature DB >> 330452

Surgical closure of myelomeningocele: Problems and consequences of the introduction of a policy of selection.

E J Guiney, R J Fitzgerald, D Mehigan, P Puri, B Sundar.   

Abstract

Mesh：

Year:  1977        PMID： 330452     DOI： 10.1007/bf03030969

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN： 0021-1265            Impact factor:   1.568


× No keyword cloud information.
  8 in total

1.  Survival of infants with unoperated myeloceles.

Authors:  M F Robards; G G Thomas; L Rosenbloom
Journal:  Br Med J       Date:  1975-10-04

2.  Spina bifida cystica. Results of treatment of 270 consecutive cases with criteria for selection for the future.

Authors:  J Lorber
Journal:  Arch Dis Child       Date:  1972-12       Impact factor: 3.791

3.  Selection for treatment in spina bifida cystica.

Authors:  G K Smith; E D Smith
Journal:  Br Med J       Date:  1973-10-27

4.  The outlook for the child with a myelomeningocele for whom early surgery was considered inadvisable.

Authors:  D W Hide; H P Williams; H L Ellis
Journal:  Dev Med Child Neurol       Date:  1972-06       Impact factor: 5.449

5.  Results of selective early operation in myelomeningocele.

Authors:  G D Stark; M Drummond
Journal:  Arch Dis Child       Date:  1973-09       Impact factor: 3.791

6.  A question of priorities.

Authors:  E J Guiney
Journal:  J Ir Med Assoc       Date:  1973-08-11

7.  Results of treatment of myelomeningocele. An analysis of 524 unselected cases, with special reference to possible selection for treatment.

Authors:  J Lorber
Journal:  Dev Med Child Neurol       Date:  1971-06       Impact factor: 5.449

8.  Early results of selective treatment of spina bifida cystica.

Authors:  J Lorber
Journal:  Br Med J       Date:  1973-10-27
  8 in total
  2 in total

1.  Perspectives in spina bifida.

Authors: 
Journal:  Br Med J       Date:  1978-09-30

2.  Results of selective treatment of spina bifida cystica.

Authors:  J Lorber; S A Salfield
Journal:  Arch Dis Child       Date:  1981-11       Impact factor: 3.791
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.